Semaglutide for atherosclerosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Apr 2023: Trial started, NCT05870462
  2. 23 May 2023: Trial registered, NCT05870462

The trials

NCT05870462: Semaglutide and Vascular Regeneration

State
State not given
Phase
Phase 4
People
100 planned
Started
29 Apr 2023
Primary completion
Dec 2024
Arms
Semaglutide
Results
None posted
  1. 29 Apr 2023: Trial started
  2. 23 May 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.